Evaluating the impact of educational interventions on use of antithrombotics in Australia

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 2, 2008, Pages 160-171

  Mandryk, John A ^a   Wai, Angela ^a   Mackson, Judith M ^a   Patterson, Craig ^a   Bhasale, Alice ^a   Weekes, Lynn M ^a  

^a National Prescribing Service   (Australia)

Author keywords

Antithrombotics; Educational intervention; Evaluation; General practitioners; Prescribing data; Time series

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTICOAGULANT AGENT; CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE; WARFARIN;

ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DRUG SAFETY; DRUG UTILIZATION; EDUCATION PROGRAM; GENERAL PRACTITIONER; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MEDICAL EDUCATION; PRESCRIPTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; TIME SERIES ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; AUSTRALIA; DATABASES, FACTUAL; DIPYRIDAMOLE; DRUG UTILIZATION; EDUCATION, MEDICAL, CONTINUING; FIBRINOLYTIC AGENTS; HUMANS; LINEAR MODELS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; TICLOPIDINE; WARFARIN;

EID: 39749166404     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1536     Document Type: Article

References (45)

1. National Prescribing Service. Using antithrombotics: maximising benefits; minimising risks, 2003 Prescribing Practice Review - PPR, December 2003.
2. National Prescribing Service. Reducing thromboembolic risk in atrial fibrillation, 2003 NPS News, National Prescribing Service Newsletter, October 2003.
3. Bloom BS. Effects of continuing medical education on improving physician clinical care and patient health: a review of systematic reviews. Int J Technol Assess Health Care 2005; 21: 380-385.
4. Avorn J, Soumerai SB. Improving drug-therapy decisions through educational outreach. A randomized controlled trial of academically based "detailing". N Engl J Med 1983; 308: 1457-1463.
5. Weekes LM, Mackson JM, Fitzgerald M, et al. National Prescribing Service: creating an implementation arm for national medicines policy. Br J Clin Pharmacol 2005; 59: 112-116.
6. Soumerai SB, Majumdar S, Lipton HL. Evaluating and improving physician prescribing. In Pharmacoepidemiology (3rd edn), Strom BL (ed.). John Wiley & Sons, Ltd.: Chichester, UK, 2000; 483-503.
7. Smith JA, Sibthorpe B. Divisions of general practice in Australia: how do they measure up in the international context? Aust New Zealand Health Policy 2007; 4, DOI:10.1186/1743-8462-4-15 (accessed 17 July 2007).
8. Scott A, Coote W. Whither Divisions of General Practice? An empirical and policy analysis of the impact of Divisions within the Australian health care system. Med J Aust 2007; 187: 95-99.
9. McManus P. Drug utilisation (letter). Med J Aust 1993; 158: 724.
10. Department of Health and Ageing. Australian Statistics on Medicines 2004-05. Commonwealth of Australia: Canberra, 2007.
11. Edmonds DJ, Dumbrell DM, Primrose JG, et al. Development of an Australian drug utilization database: a report from the Drug Utilization Sub-Committee of the Pharmaceutical Benefits Advisory Committee. PharmacoEconomics 1993; 3: 427-432.
12. Robertson J, Fryer JL, O'Connell DL, et al. Limitations of Health Insurance Commission (HIC) data for deriving prescribing indicators. Med J Aust 2002; 176: 419-424.
13. Robertson J, Henry D, Dobbins T, et al. Prescribing patterns in general practice - a comparison of two data sources. Aust Fam Physician 1999; 28: 1186-1190.
14. Britt H, Miller CG, Charles J, et al. General Practice Activity in Australia 2005-06. University of Sydney and the Australian Institute of Health and Welfare: Sydney, 2007.
15. Britt H, Miller G, Bayram C. The quality of data on general practice - A discussion of BEACH reliability and validity. Aust Fam Physician 2007; 36: 36-40.
16. AIHW GP Statistics and Classification Unit. Secondary prevention of heart attack or stroke. University of Sydney: Sydney, Block 90B SAND from the BEACH program, 2007.
17. AIHW GP Statistics and Classification Unit. Secondary prevention of heart attack or stroke. University of Sydney: Sydney, SAND abstract No. 54 from the BEACH program, 2003; http://pandora.nla.gov.au/tep/14007 [10 May 2007].
18. Mandryk JA, Mackson JM, Horn FE, et al. Measuring change in prescription drug utilization in Australia. Pharmacoepidemiol Drug Saf 2006; 15: 477-484.
19. Medicare Australia. Medicare Benefits Schedule (MBS) Item Statistics Reports. Medicare Australia, 2007; http://www.medicareaustralia.gov.au/ statistics/dyn_mbs/forms/mbs_tab4.shtml [15 February 2007].
20. McManus P, Donnelly N, Henry D, et al. Prescription drug utilization following patient co-payment changes in Australia. Pharmacoepidemiol Drug Saf 1996; 5: 385-392.
21. Donnelly N, McManus P, Dudley J, et al. Impact of increasing the re-supply interval on the seasonality of subsidised prescription use in Australia. Aust N Z J Public Health 2000; 24: 603-606.
22. Horn FE, Mandryk JA, Mackson JM, et al. Measurement of changes in antihypertensive drug utilisation following primary care educational interventions. Pharmacoepidemiol Drug Saf 2007; 16: 297-308.
23. Makridakis S, Wheelright S, Hyndman RJ. Forecasting: Methods and Applications. New York, John Wiley & Sons: 1998.
24. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2007; http://www.R-project.org [4 June 2007].
25. Cleveland RB, Cleveland WS, McRae JE, et al. STL: a seasonal-trend decomposition procedure based on Loess (with discussion). J Off Stat 1990; 6: 3-73.
26. May FW, Rowett DS, Gilbert AL, et al. Outcomes of an educational-outreach service for community medical practitioners: non-steroidal anti-inflammatory drugs. Med J Aust 1999; 170: 471-474.
27. Baker RI, Coughlin PB, Gallus AS, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181: 492-497.
28. Ross-Degnan D, Soumerai SB, Fortess EE, et al. Examining product risk in context: market withdrawal of zomepirac as a case study. JAMA 1993; 270: 1937-1942.
29. Hankey GJ. Non-valvular atrial fibrillation and stroke prevention. Med J Aust 2001; 174: 234-239.
30. Australian Institute of Health and Welfare. Medicines for Cardiovascular Health: Are They Used Appropriately? Australian Institute of Health and Welfare: Canberra, 2007.
31. Australian Institute of Health and Welfare. Procedures data cubes: number of angioplasty procedures. Australian Institute of Health and Welfare, 2007. http://www.aihw.gov.au/hospitals/datacubes/ datacube_proc.cfm [15 February 2007].
32. Australian Institute of Health and Welfare. Coronary angioplasty in Australia 1999. AIHW: Canberra, and National Heart Foundation of Australia, 2002.
33. Harper RW. Drug-eluting coronary stents - a note of caution. Med J Aust 2007; 186: 253-255.
34. Therapeutic Guidelines Limited. Therapeutic Guidelines: Cardiovascular - Version 4. Therapeutic Guidelines Limited: Melbourne, 2003.
35. Australian Medicines Handbook Pty Ltd. Australian Medicines Handbook. Adelaide South Australia, Australia, 2007.
36. Roughead EE, Gilbert AL, Primrose JG. Improving drug use: a case study of events which led to changes in use of flucloxacillin in Australia. Soc Sci Med 1999; 48: 845-853.
37. Adverse Drugs Reactions Advisory Committee. Australian Adverse Drug Reactions Bulletin. Australian Government: Canberra, 2007; http://www.tga.gov.au/adr/aadrb.htm [27 June 2007].
38. Roughead EE. Managing adverse drug reactions: time to get serious (Editorial). Med J Aust 2005; 182: 264-265.
39. Roberts GW, Adams R. Impact of introducing anticoagulation-related prescribing guidelines in a hospital setting using academic detailing. Ther Clin Risk Manag 2006; 2: 309-316.
40. Thomson R, Parkin D, Eccles M, et al. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet 2000; 355: 956-962.
41. The Clinical Quality Improvement Network Investigators. Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. Can J Cardiol 1998; 14: 695-702.
42. Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160: 41-46.
43. Bajorek BV, Ogle SJ, Duguid MJ, et al. Management of warfarin in atrial fibrillation: views of health professionals, older patients and their carers. Med J Aust 2007; 186: 175-180.
44. Soumerai SB, Ross-Degnan D, Fortress EE, et al. A critical analysis of studies of State Drug Reimbursement Policies: research in need of discipline. Milbank Q 1993; 71: 217-252.
45. Schoen C, Osborn R, Huynh PT, et al. Taking the pulse of health care systems: experiences of patients with health problems in six countries. Health Aff 2005; 16: W5-509-W5-525.